 Results Among the 400 patients receiving curative treatment, five-year survival was 22.8 91 patients. Cytarabine consolidation dose was an independent determinant of survival significant differences were found among the groups, whereas age, karyotype, induction protocol, French-American-British classification and etiology were not. In comparison with the very-high-dose group, the risk of death was 3.871 times 95 CI, 1.043 to 14.370 times higher in the high-dose group p0.043 and 9.775 times 95 CI, 2.493 to 38.320 times higher in the low-dose group p0.001, assuming, in both cases, that age, karyotype, French-American-British classification and etiology of acute myeloid leukemia were constant. 